Yesterday, the Wall Street analyst firm of Needham & Co. initiated coverage on Cytokinetics Inc. (CYTK) issuing a “Buy” rating and a $2.50 price target. The biopharmaceutical penny stock has not seen $2.50 in over 18 months and just agreed to sell an additional 55.92 million shares with 33.55 million attached warrants to Cowen and Co. LLC for $56 million. Seeing as ...
Continue Reading →
3
JUL
JUL
0
Share